One-year Prospective, Observational Study of the Journey of Patients With Plaque Psoriasis Prescribed Calcipotriol/Betamethasone Aerosol Foam or Other Topical Therapy (PSOREAL)

NCT02935582 COMPLETED

Multinational real-life study of current psoriasis treatment strategies, topical treatment patterns and treatment outcomes of these treatments, including the newly introduced calcipotriol/betamethasone dipropionate aerosol foam fixed combination product Enstilar® (calcipotriol/betamethasone dipropionate).

Details

Lead sponsor	LEO Pharma
Status	COMPLETED
Enrolment	1214
Start date	2017-01
Completion	2020-12-30

Conditions

• Psoriasis Vulgaris

Interventions

• Enstilar® aerosol foam
• Other topical

Primary outcomes

• PaGA — 4 weeks
  Patient reported Global Assessment
• Itch — 1 week
  Itch dimension of Psoriasis Symptom Inventory (PSI) questionnaire
• Switch — 1 year
  Time to switch of topical treatment strategy
• Flare-up — 1 year
  Time to first flare-up after initial treatment completion

Countries

Canada, Sweden, United Kingdom